Literature DB >> 26168339

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity.

José Vicente Pérez-Girón1, Sergio Gómez-Medina1, Anja Lüdtke1, Cesar Munoz-Fontela2.   

Abstract

Vaccines are one of the greatest achievements of mankind, and have saved millions of lives over the last century. Paradoxically, little is known about the physiological mechanisms that mediate immune responses to vaccines perhaps due to the overall success of vaccination, which has reduced interest into the molecular and physiological mechanisms of vaccine immunity. However, several important human pathogens including influenza virus still pose a challenge for vaccination, and may benefit from immune-based strategies. Although influenza reverse genetics has been successfully applied to the generation of live-attenuated influenza vaccines (LAIVs), the addition of molecular tools in vaccine preparations such as tracer components to follow up the kinetics of vaccination in vivo, has not been addressed. In addition, the recent generation of mouse models that allow specific depletion of leukocytes during kinetic studies has opened a window of opportunity to understand the basic immune mechanisms underlying vaccine-elicited protection. Here, we describe how the combination of reverse genetics and chimeric mouse models may help to provide new insights into how vaccines work at physiological and molecular levels, using as example a recombinant, cold-adapted, live-attenuated influenza vaccine (LAIV). We utilized laboratory-generated LAIVs harboring cell tracers as well as competitive bone marrow chimeras (BMCs) to determine the early kinetics of vaccine immunity and the main physiological mechanisms responsible for the initiation of vaccine-specific adaptive immunity. In addition, we show how this technique may facilitate gene function studies in single animals during immune responses to vaccines. We propose that this technique can be applied to improve current prophylactic strategies against pathogens for which urgent medical countermeasures are needed, for example influenza, HIV, Plasmodium, and hemorrhagic fever viruses such as Ebola virus.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26168339      PMCID: PMC4544921          DOI: 10.3791/52803

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  14 in total

1.  In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens.

Authors:  Steffen Jung; Derya Unutmaz; Phillip Wong; Gen-Ichiro Sano; Kenia De los Santos; Tim Sparwasser; Shengji Wu; Sri Vuthoori; Kyung Ko; Fidel Zavala; Eric G Pamer; Dan R Littman; Richard A Lang
Journal:  Immunity       Date:  2002-08       Impact factor: 31.745

2.  Generation of recombinant influenza virus from plasmid DNA.

Authors:  Luis Martínez-Sobrido; Adolfo García-Sastre
Journal:  J Vis Exp       Date:  2010-08-03       Impact factor: 1.355

3.  Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair.

Authors:  Jeremy S Duffield; Stuart J Forbes; Christothea M Constandinou; Spike Clay; Marina Partolina; Srilatha Vuthoori; Shengji Wu; Richard Lang; John P Iredale
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

4.  Mucosal polyinosinic-polycytidylic acid improves protection elicited by replicating influenza vaccines via enhanced dendritic cell function and T cell immunity.

Authors:  José V Pérez-Girón; Alan Belicha-Villanueva; Ebrahim Hassan; Sergio Gómez-Medina; Jazmina L G Cruz; Anja Lüdtke; Paula Ruibal; Randy A Albrecht; Adolfo García-Sastre; César Muñoz-Fontela
Journal:  J Immunol       Date:  2014-06-23       Impact factor: 5.422

Review 5.  Dendritic cells and the control of immunity.

Authors:  J Banchereau; R M Steinman
Journal:  Nature       Date:  1998-03-19       Impact factor: 49.962

6.  Impaired CD8(+) T cell immunity after allogeneic bone marrow transplantation leads to persistent and severe respiratory viral infection.

Authors:  Kymberly M Gowdy; Tereza Martinu; Julia L Nugent; Nicholas D Manzo; Helen L Zhang; Francine L Kelly; Michael J Holtzman; Scott M Palmer
Journal:  Transpl Immunol       Date:  2014-11-05       Impact factor: 1.708

7.  Understand memory, design better vaccines.

Authors:  Michael J Bevan
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

Review 8.  Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines.

Authors:  R J Cox; K A Brokstad; P Ogra
Journal:  Scand J Immunol       Date:  2004-01       Impact factor: 3.487

9.  Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans.

Authors:  Troy D Querec; Rama S Akondy; Eva K Lee; Weiping Cao; Helder I Nakaya; Dirk Teuwen; Ali Pirani; Kim Gernert; Jiusheng Deng; Bruz Marzolf; Kathleen Kennedy; Haiyan Wu; Soumaya Bennouna; Herold Oluoch; Joseph Miller; Ricardo Z Vencio; Mark Mulligan; Alan Aderem; Rafi Ahmed; Bali Pulendran
Journal:  Nat Immunol       Date:  2008-11-23       Impact factor: 25.606

10.  Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage.

Authors:  Matthew M Meredith; Kang Liu; Guillaume Darrasse-Jeze; Alice O Kamphorst; Heidi A Schreiber; Pierre Guermonprez; Juliana Idoyaga; Cheolho Cheong; Kai-Hui Yao; Rachel E Niec; Michel C Nussenzweig
Journal:  J Exp Med       Date:  2012-05-21       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.